Subgroup of showed a negligible effect in favour of ivabradine (hazard ratio of 0.99). Secondary endpoints in RS population All-cause in all the pre-specified except for the subgroup on mortality subgroups except in the baseline heart rate (p=0.0274) subgroup of HR in favour of patients with “baseline <77bpm” baseline HR 77 bpm versus those with <77 bpm Cardiovascular in all the pre-specified except for the subgroup on death subgroups except in the baseline heart rate (p=0.0379) subgroup of HR in favour of patients with “baseline <77bpm” baseline HR 77 bpm versus those with <77 bpm Death from heart in all the pre-specified NA failure subgroups except in the subgroup of HR “baseline <77bpm” All-cause NA NA hospitalisation Cardiovascular NA NA hospitalisation Hospitalisation in all the pre-specified except for the subgroup on for worsening subgroups. ischaemic versus heart failure cause (p=0.0345) in favour of patients with CHF from an ischaemic cause versus those with CHF from a cause Secondary endpoints in RSBBdose population All-cause Only the subgroups of All the interaction tests had mortality cause”, higher than 0.05 “females”, “ischaemic Class II”, “NYHA “no hypertension” and HR “baseline 77 bpm” Cardiovascular Only the subgroups of NA death cause”, “females”, “ischaemic Class II”, “NYHA “no hypertension”, HR 77 “baseline bpm”, 65 years”, and “age “no DM” Hospitalisation in all the pre-specified NA for worsening subgroups except the subgroup heart failure of 65 years”. “age
Subgroup of showed a negligible effect in favour of ivabradine (hazard ratio of 0.99). Secondary endpoints in RS population All-cause mortality in all the pre-specified subgroups except in the subgroup of “baseline HR <77bpm” except for the subgroup on baseline heart rate (p=0.0274) in favour of patients with baseline HR 77 bpm versus those with <77 bpm Cardiovascular death in all the pre-specified subgroups except in the subgroup of “baseline HR <77bpm” except for the subgroup on baseline heart rate (p=0.0379) in favour of patients with baseline HR 77 bpm versus those with <77 bpm Death from heart failure in all the pre-specified subgroups except in the subgroup of “baseline HR <77bpm” NA All-cause hospitalisation NA NA Cardiovascular hospitalisation NA NA Hospitalisation for worsening heart failure in all the pre-specified subgroups. except for the subgroup on ischaemic versus cause (p=0.0345) in favour of patients with CHF from an ischaemic cause versus those with CHF from a cause Secondary endpoints in RSBBdose population All-cause mortality Only the subgroups of “females”, “ischaemic cause”, “NYHA Class II”, “no hypertension” and “baseline HR 77 bpm” All the interaction tests had higher than 0.05 Cardiovascular death Only the subgroups of “females”, “ischaemic cause”, “NYHA Class II”, “no hypertension”, “baseline HR 77 bpm”, “age 65 years”, and “no DM” NA Hospitalisation for worsening heart failure in all the pre-specified subgroups except the subgroup of “age 65 years”. NA
auspar-ivabradine-121031.docx